Abstract
<h2>ABSTRACT</h2> The isolation and physicochemical characterization of four crystalline modifications of brodimoprim (5-[(4-bromo-3,5-dimethoxyphenyl)methyl]-2,4-pyrimidinediamine, hereinafter BMP), a structural analog of trimethoprim (TMP), are reported. These phases include an unsolvated form of BMP, a hemihydrate (BMP·0.5H<sub>2</sub>O), a 1:1 solvate containing isopropanol (BMP·C<sub>3</sub>H<sub>7</sub>OH(iso)), and a hemichloroformate (BMP·0.5CHCl<sub>3</sub>). Unsolvated BMP was isolated both by recrystallization from a range of common solvents as well as by thermal decomposition of the above solvates and no evidence for polymorphism was found. PXRD data indicated that the three solvates crystallize in different arrangements. Data from thermal analysis (thermogravimetry (TGA), hot stage microscopy (HSM), differential scanning calorimetry (DSC)) of the solvates containing water and iso-propanol were interpreted on the basis of their single-crystal X-ray structures which revealed that the modes of solvent inclusion in BMP·0.5H<sub>2</sub>O and BMP·C<sub>3</sub>H<sub>7</sub>OH(iso) may be described as ‘isolated site' and ‘lattice channel' type inclusions, respectively. © 2007 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 96: 996–1007, 2007
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
